Claims for Patent: 11,278,622

Summary for Patent: 11,278,622

Title:	Ceftolozane antibiotic compositions
Abstract:	This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.
Inventor(s):	Terracciano; Joseph (Concord, MA), Damour; Nicole Miller (Belmont, MA), Jiang; Chun (Hillsborough, CA), Fogliato; Giovanni (Barzana, IT), Donadelli; Giuseppe Alessandron (Lodi, IT), Resemini; Dario (Milan, IT)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	16/574,825
Patent Claims:	1. A method for treating an infection which is a nosocomial pneumonia infection in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane sulfate and tazobactam sodium, said composition comprising less than 0.15% of a compound of formula (III) ##STR00018## relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 1 month at a temperature of 25.degree. C. and at a relative humidity of 60%, wherein the ceftolozane sulfate and tazobactam sodium provide ceftolozane active and tazobactam active in a ratio of 2:1 by weight. 2. The method of claim 1, wherein the infection is a hospital acquired bacterial pneumonia infection. 3. The method of claim 1, wherein the infection is a ventilator-associated bacterial pneumonia infection. 4. The method of claim 1, wherein the composition contains less than 0.1% of the compound of formula (III) relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 1 month at a temperature of 25.degree. C. and at a relative humidity of 60%. 5. The method of claim 1, wherein the composition contains less than 0.03% of the compound of formula (III) relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm when stored as a solid for 1 month at a temperature of 25.degree. C. and at a relative humidity of 60%. 6. The method of claim 1, wherein the composition the amount of ceftolozane active is 2,000 mg and the amount of tazobactam active is 1,000 mg. 7. The method of claim 1, wherein the composition is provided in a unit dosage form. 8. The method of claim 6, wherein the composition is provided in a unit dosage form. 9. The method of claim 1, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by parenteral administration. 10. The method of claim 1, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by intravenous infusion. 11. The method of claim 2, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by intravenous infusion. 12. The method of claim 3, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by intravenous infusion. 13. The method of claim 6, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by intravenous infusion. 14. A method for treating an infection which is a nosocomial pneumonia infection in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane sulfate and tazobactam sodium, said composition comprising less than 0.15% of the compound of formula (III) ##STR00019## relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, and less than 1.5% of a compound of formula (IV) ##STR00020## relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 3 months at a temperature of 25.degree. C. and at a relative humidity of 60%, wherein the ceftolozane sulfate and tazobactam sodium provide ceftolozane active and tazobactam active in a ratio of 2:1 by weight. 15. The method of claim 14, wherein the infection is a hospital acquired bacterial pneumonia infection. 16. The method of claim 14, wherein the infection is a ventilator-associated bacterial pneumonia infection. 17. The method of claim 14, wherein the composition contains less than 0.05% of the compound of formula (III) relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 3 months at a temperature of 25.degree. C. and at a relative humidity of 60%. 18. The method of claim 14, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by intravenous infusion. 19. A method for treating an infection which is a nosocomial pneumonia infection in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane sulfate and tazobactam sodium, said composition comprising less than 0.15% relative to ceftolozane sulfate of the compound having a mass spectra depicted in FIG. 14, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 1 month at a temperature of 25.degree. C. and at a relative humidity of 60%, wherein the ceftolozane sulfate and tazobactam sodium provide ceftolozane active and tazobactam active in a ratio of 2:1 by weight, wherein the structure of the compound depicted in the mass spectra of FIG. 14 is: ##STR00021## 20. The method of claim 19, wherein the infection is a hospital acquired bacterial pneumonia infection. 21. The method of claim 19, wherein the infection is a ventilator-associated bacterial pneumonia infection. 22. The method of claim 19, wherein the composition contains less than 0.1% relative to ceftolozane sulfate of the compound with the mass spectra depicted in FIG. 14, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 1 month at a temperature of 25.degree. C. and at a relative humidity of 60%. 23. The method of claim 19, wherein the composition contains less than 0.03% relative to ceftolozane sulfate of the compound with the mass spectra depicted in FIG. 14, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 1 month at a temperature of 25.degree. C. and at a relative humidity of 60%. 24. The method of claim 19, wherein the composition the amount of ceftolozane active is 2,000 mg and the amount of tazobactam active is 1,000 mg. 25. The method of claim 19, wherein the composition is provided in a unit dosage form. 26. The method of claim 24, wherein the composition is provided in a unit dosage form. 27. The method of claim 19, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by intravenous infusion. 28. A method for treating an infection which is a nosocomial pneumonia infection in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane sulfate and tazobactam sodium, said composition comprising less than 0.15% relative to ceftolozane sulfate of a compound having a mass spectra depicted in FIG. 14, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, and less than 1.5% of a compound of formula (IV): ##STR00022## relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 3 months at a temperature of 25.degree. C. and at a relative humidity of 60%, wherein the ceftolozane sulfate and tazobactam sodium provide ceftolozane active and tazobactam active in a ratio of 2:1 by weight, wherein the structure of the compound depicted in the mass spectra of FIG. 14 is: ##STR00023## 29. The method of claim 28, wherein the infection is a hospital acquired bacterial pneumonia infection. 30. The method of claim 28, wherein the infection is a ventilator-associated bacterial pneumonia infection. 31. The method of claim 28, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by intravenous infusion.